09:24 AM EDT, 03/28/2024 (MT Newswires) -- Ankur Dhingra, Chief Financial Officer, on March 26, 2024, executed a purchase for 100,000 shares in Summit Therapeutics ( SMMT ) for $375,000. Following the Form 4 filing with the SEC, Dhingra has control over a total of 354,958 shares of the company, with 354,958 shares controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1599298/000159929824000046/xslF345X03/wk-form4_1711585608.xml
Price: 4.05, Change: +0.3, Percent Change: +8